Peter Moosmann
Vascular endothelial growth factor A amplification in colorectal cancer is associated with reduced M1 and M2 macrophages and diminished PD-1-expressing lymphocytes
Burmeister K, Tornillo L, Piscuoglio S, Ng C, Köberle D, Lehmann F, Moosmann P, Horber D, Jochum W, Grobholz R, Perrina V, Matter M, Eppenberger-Castori S, Andreozzi M, Quagliata L, Terracciano L. Vascular endothelial growth factor A amplification in colorectal cancer is associated with reduced M1 and M2 macrophages and diminished PD-1-expressing lymphocytes. PloS one 2017; 12:e0175563.
12.04.2017Vascular endothelial growth factor A amplification in colorectal cancer is associated with reduced M1 and M2 macrophages and diminished PD-1-expressing lymphocytes
12.04.2017PloS one 2017; 12:e0175563
Burmeister Katharina, Tornillo Luigi, Piscuoglio Salvatore, Ng Charlotte K Y, Köberle Dieter, Lehmann Frank, Moosmann Peter, Horber Daniel, Jochum Wolfram, Grobholz Rainer, Perrina Valeria, Matter Matthias S, Eppenberger-Castori Serenella, Andreozzi Mariacarla, Quagliata Luca, Terracciano Luigi M
Cetuximab in combination with chemoradiotherapy before surgery in patients with resectable, locally advanced esophageal carcinoma: a prospective, multicenter phase IB/II Trial (SAKK 75/06)
Ruhstaller T, Brauchli P, Inauen R, Widmer L, Mingrone W, Gautschi O, Rauch D, Schneider P, Montemurro M, Moosmann P, von Moos R, Kranzbuehler H, Dietrich D, Pless M, Hess V. Cetuximab in combination with chemoradiotherapy before surgery in patients with resectable, locally advanced esophageal carcinoma: a prospective, multicenter phase IB/II Trial (SAKK 75/06). J Clin Oncol 2011; 29:626-31.
04.01.2011Cetuximab in combination with chemoradiotherapy before surgery in patients with resectable, locally advanced esophageal carcinoma: a prospective, multicenter phase IB/II Trial (SAKK 75/06)
04.01.2011J Clin Oncol 2011; 29:626-31
Ruhstaller Thomas, Brauchli Peter, Inauen Roman, Widmer Lucas, Mingrone Walter, Gautschi Oliver, Rauch Daniel, Schneider Paul M, Montemurro Michael, Moosmann Peter, von Moos Roger, Kranzbuehler Helmut, Dietrich Daniel, Pless Miklos, Hess Viviane
Is a change in patient-reported dysphagia after induction chemotherapy in locally advanced esophageal cancer a predictive factor for pathological response to neoadjuvant chemoradiation?
Ribi K, Pestalozzi B, Lombriser N, Borner M, von Moos R, Moosmann P, Hess V, Roth A, Honegger H, Schuller J, Köberle D, Ruhstaller T. Is a change in patient-reported dysphagia after induction chemotherapy in locally advanced esophageal cancer a predictive factor for pathological response to neoadjuvant chemoradiation?. Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer 2009; 17:1109-1116.
07.02.2009Is a change in patient-reported dysphagia after induction chemotherapy in locally advanced esophageal cancer a predictive factor for pathological response to neoadjuvant chemoradiation?
07.02.2009Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer 2009; 17:1109-1116
Ribi Karin, Pestalozzi Bernhard, Lombriser Norbert, Borner Markus, von Moos Roger, Moosmann Peter, Hess Viviane, Roth Arnaud, Honegger Hanspeter, Schuller Jan C, Köberle Dieter, Ruhstaller Thomas